Product category:
Contract research
News Release from: Chiltern International | Subject: French Economic Ministry
Edited by the Laboratorytalk Editorial
Team on 16 March 2004
French lessons
Chiltern participates in French government initiative as it plans France's future in pharmaceutical research and development
Chiltern International has been consulted by a delegation from the French Economic Ministry in an attempt by the government to boost France's standing in the international healthcare industry In the past year the French government has launched several initiatives to sustain innovation, including reforming the R and D tax credit scheme and creating a new fiscal status for emerging innovative companies
This article was originally published on Laboratorytalk on 10 Feb 2004 at 8.00am (UK)
Related stories
General manager for Chiltern France
Claude Albrecht will be responsible for ensuring high levels of service to clients, focussing on the development of the French operation
Long term strategy the key to success
In a recent lecture to biomedical students at Kings College London, Faiz Kermani outlined how more and more R and D projects have been given the green light over the last six months
All are designed to enhance France's competitive position in the international healthcare industries and make the most of the opportunities in the industry as R and D expenditure enters a healthier phase after two quiet years.
Francis Mer, the French minister for the economy, finance and industry, and Nicole Fontaine, minister delegate for industry, have commissioned a fact-finding report to come up with various recommendations and as part of that process has had several consultations with British companies, including Chiltern International.
Faiz Kermani and Yohan Vezinhet, representatives of Chiltern's business development team, recently met the French delegation during an information-gathering trip spanning several European countries.
"Chiltern's expertise and knowledge of the sector, combined with its geographical spread in the UK, USA and mainland Europe will make our views and experiences very relevant for the French government initiatives," explained Kermani.
"The UK provides an interesting example to other countries, as it has been particularly proactive in improving the environment for biopharmaceutical R and D".
"We found Chiltern's views regarding the pharmaceutical industry both in France and in the rest of Europe very informative," commented Benoit Colinot, commercial attache at the French Embassy in London.
"This provided us with many points to follow up concerning how France could improve its R and D environment".
• Chiltern International: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
